HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dudal, S. Articles by Lafont, V. Search for Related Content PubMed PubMed Citation Articles by Dudal, S. Articles by Lafont, V.

Release of LL-37 by Activated Human V9V2 T Cells: A Microbicidal Weapon against Brucella suis¹

Institut National de la Santé et de la Recherche Médicale, Unité 431, Université Montpellier 2, Montpellier, France

Human V9V2 T cells play a crucial role in early immune response to intracellular pathogens. Moreover, in brucellosis, these cells are drastically increased in the peripheral blood of patients during the acute phase of infection. In vitro, V9V2 T cells are capable of inhibiting Brucella growth and development through a combination of mechanisms: 1) cytotoxicity, 2) macrophage activation and bactericidal activity through cytokine and chemokine secretion, and 3) antibacterial effects. We previously described that antibacterial factors were found in supernatants from activated V9V2 T cells. In this study, we show that V9V2 T cells express the human cathelicidin hCAP18 and its mature form, known as LL-37, is released upon activation of V9V2 T cells. We also show that LL-37 has an antibacterial effect on Brucella suis. Overall, our results demonstrate that LL-37 is a soluble factor responsible for a part of the bactericidal activity of V9V2 T cells.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ This study was supported in part by European Commission Grant QLK2-1999-0014 and an Ecos-Anuies program (Franco-Mexico) grant (Action No. PM990S01).

² Address correspondence and reprint requests to Dr. Virginie Lafont, Institut National de la Santé et de la Recherche Médicale, Unité 431, Université Montpellier 2, Place Eugene Bataillon, CC 100, 34095 Montpellier Cedex 05, France. E-mail address: vlafont{at}univ-montp2.fr

³ Abbreviations used in this paper: HMB-PP, (E)-4-hydroxy-3-methyl-but-2-enyl-pyrophosphate; TS, tryptic soy broth; DC, dendritic cell; A, activated; NA, nonactivated.

This article has been cited by other articles:

				J. Liautard, S. Ouahrani-Bettache, V. Jubier-Maurin, V. Lafont, S. Kohler, and J.-P. Liautard Identification and Isolation of Brucella suis Virulence Genes Involved in Resistance to the Human Innate Immune System Infect. Immun., November 1, 2007; 75(11): 5167 - 5174. [Abstract] [Full Text] [PDF]

				K.-J. Puan, C. Jin, H. Wang, G. Sarikonda, A. M. Raker, H. K. Lee, M. I. Samuelson, E. Marker-Hermann, L. Pasa-Tolic, E. Nieves, et al. Preferential recognition of a microbial metabolite by human V{gamma}2V{delta}2 T cells Int. Immunol., May 1, 2007; 19(5): 657 - 673. [Abstract] [Full Text] [PDF]